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Summary
Adult humanmesenchymal stromal or stem cells (MSC) can differentiate into
a variety of cell types and are candidate cellular therapeutics in regenerative
medicine. Surprisingly, these cells also display multiple potent immuno-
modulatory capabilities, including allosuppression, making allogeneic cell
therapy a possibility. The exact mechanisms involved in regulatory T cell
induction by allogeneic human MSC was examined, using purified CD4+
populations and well-characterized bone marrow-derived adult humanMSC.
Allogeneic MSC were shown to induce forkhead box P3 (FoxP3)+ and CD25+
mRNA and protein expression in CD4+ T cells. This phenomenon required
direct contact betweenMSC and purified T cells, although cell contact was not
required for MSC induction of FoxP3 expression in an unseparated mono-
nuclear cell population. In addition, through use of antagonists and neutral-
izing antibodies, MSC-derived prostaglandins and transforming growth
factor (TGF)-b1 were shown to have a non-redundant role in the induction of
CD4+CD25+FoxP3+ T cells. Purified CD4+CD25+ T cells induced by MSC
co-culture expressed TGF-b1 and were able to suppress alloantigen-driven
proliferative responses in mixed lymphocyte reaction. These data clarify the
mechanisms of human MSC-mediated allosuppression, supporting a sequen-
tial process of regulatory T cell induction involving direct MSC contact with
CD4+ cells followed by both prostaglandin E2 and TGF-b1 expression.Overall,
this study provides a rational basis for ongoing clinical studies involving
allogeneic MSC.
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Introduction
Mesenchymal stem cells or mesenchymal stromal cells
(MSC) have the capacity to differentiate into cell types of the
mesenchymal lineage [1,2], and contribute to haematopoie-
sis [3,4] and the resolution of physiological insult [5]. These
characteristics have prompted the clinical use of MSC in
regenerative and cell therapies [6–8]. However, MSC possess
another attribute attractive for cell-based therapy – they
display potent immunosuppressive qualities [9–11]. Conse-
quently, MSC-based approaches for graft-versus-host disease
(GVHD) and other immune pathologies are being explored.
Extensive research has focused upon the mechanisms behind
MSC-mediated immunosuppressive activity. Although these
mechanisms remain to be elucidated fully, it is now clear that
MSC can suppress allogeneic responses [10,12–14]. In effect,
MSC modulate different aspects of the rejection process,
including the preservation of dendritic cell (DC) immaturity
[15], skewing of CD4+ T helper population phenotypes
and modulation of CD8+ cytotoxic T lymphocyte and
natural killer cell functions [16,17]. These attributes
provide a rationale for potential allogeneic therapies against
diabetes, autoimmune diseases and organ transplant
rejection.
Modulation of regular allorejection processes by MSC is
multi-factorial, requiring different contact-dependent and
-independent signals under different circumstances. It is
now clear that modulation of DC maturation by MSC
requires interleukin (IL)-6 and a contact-dependent signal
[12,15], whereas full suppression of T cell function by MSC
(both human and murine) involves some degree of MSC
activation or ‘licensing’ thought to involve interferon
(IFN)-g in conjunction with IL-1a, IL-1b or tumour
necrosis factor-a [18]. Non-specific suppression of T cell
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proliferation is mediated by soluble factors such as trans-
forming growth factor (TGF)-b, kynurenine, [9,19,20]
prostaglandin E2 (PGE2) [19–21], nitric oxide [22], haem
oxygenase products [23] and insulin-like growth factor
binding protein [24]. In addition to these mechanisms, there
is increasing evidence that MSC modulation of T cell
responses is more subtle than simple induction of global
suppression. For example, MSC inhibit proliferation but not
all effector functions of T cells [11,25], a condition similar
to that of division arrest anergy [26] and also reminiscent of
the split suppression seen in regional mucosal immune
responses [27]. However, there is insufficient understanding
of how MSC induce the expansion of regulatory T cells (Treg)
[21,28].
Peripheral tolerance is an active phenomenon that
involves regulatory CD4+ T cells [29] including regulatory T
Treg that co-express surface CD4 and CD25. The mechanisms
that generate Treg are not elucidated fully; however, the tran-
scription factor forkhead box P3 (FoxP3) is known to play a
role in both natural and induced Treg differentiation from
non-committed precursors [30,31]. The selective induction
of Tregs can be promoted by a number of factors, including
DC maturation status or small molecules such as IL-10,
TGF-b and PGE2 [32,33].
The present study sought to determine if human MSC
exert their immunosuppressive activity by manipulating the
immune system through the selective induction of regula-
tory CD4+ T cells, and to define the mechanisms essential
for this to occur. The capacity of MSC to induce CD4+
CD25+ FoxP3+ Treg was examined, and the requirement for
different MSC-derived soluble factors characterized
through neutralization or chemical antagonism. Finally,
MSC-induced regulatory CD4+ T cells were isolated and
examined for their functional capability to modulate allo-
responses in vitro.
Material and methods
Cell isolation, purification and culture
Human MSC were isolated and expanded from aspirates of
bone marrow by direct plating,as described previously [2,34].
Cultures were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% (v/v) fetal calf
serum and 1% (v/v) penicillin/streptomycin (Invitrogen-
Gibco, Paisley, Scotland, UK). Contamination in MSC popu-
lations is a key confounding variable, therefore rigorous
quality control was adopted to ensure that MSC were not
contaminated with haematopoietic or other cell types, and
that cells retained differentiation capacity as described previ-
ously [2,34]. Human CD4+ T cells were isolated from periph-
eral blood mononuclear cells (PBMC) using a MagCellect
CD4+ T cell negative selection, isolation kit according to
the manufacturer’s instructions (R&D Systems, Abingdon,
Oxon, UK). CD4+ T cells were co-cultured with MSC at a ratio
of 3:1 (CD4+ : MSC), a ratio determined to be the optimal
dose for MSC modulation of T cells and DC. Similarly, for
transwell experiments, MSC were cultured in the tissue
culture insert incorporating a 0·4 mm membrane placed in
the wells of six- or 24-well plates (Greiner Bio-one, Stone-
house, Glos, UK), while CD4+ T cells were cultured in the well
beneath the insert. Study design and use of human mesen-
chymal stem cells was approved by the bioethics committees
of the National University of Ireland Maynooth and the
National University of Ireland Galway.
Characterization of human MSC surface marker
expression and differentiation potential
Human MSC were detached from substrate with trypsin/
ethylenediamine tetraacetic acid (EDTA), washed and resus-
pended in phosphate-buffered saline (PBS) with 1% (v/v)
bovine serum albumin. Cells (1 ¥ 105) were incubated with
fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-
conjugated monoclonal antibodies for 15 min at 4°C,
washed and then analysed by flow cytometry. Antibodies
recognizing the following human antigens or appropriate
isotype controls were used: human leucocyte antigen (HLA)-
ABC, HLA-DR, CD106, CD117 (eBioscience, San Diego, CA,
USA), CD11b, CD29, CD31, CD34, CD44, CD45, CD54,
CD105 (Immunotools, Friesoythe, Germany) and CD90
(BD Biosciences, Oxford, UK).
Human MSC were examined for their ability to differ-
entiate into adipocytes, osteoblasts and chondrocytes.
Adipogenic differentiation was induced by 1 mM dexame-
thasone, 200 mM indomethacin, 10 mg insulin and 500 mM
3-isobutyl-methyl-xanthine, and osteogenic differentiation
was induced by 100 nM dexamethasone, 10 mM b-
glycerolphosphate and 50 mM ascorbic acid-2-phosphate.
For chondrogenic differentiation a pellet culture system was
used. Some 2 ¥ 105 cells were centrifuged in a 15 ml polypro-
pylene tube. The pellet was cultured at 37°C in 5% CO2 in
500 ml chondrogenic media containing high-glucose DMEM
supplemented with 10 ng/ml human TGF-B3 (TS:beta)
(R&D Systems), 100 nM dexamethasone, 50 ug/ml ascorbic
acid-2-phosphate, 40 ug/ml proline, 1 mM sodium pyruvate
and (1:99) ITS + supplement (BD Biosciences). Differentia-
tion cultures were harvested after 21 days. Oil red O and
Alizarin red S were used to identify adipocytes and osteo-
blasts respectively. Chondrogenic pellets were harvested on
day 21 for glycosaminoglycan (GAG) quantitation. Briefly,
chondrogenic pellets were washed with Dulbecco’s PBS and
digested with papain solution (1 mg/ml in 50 mM sodium
phosphate, pH 6·5 containing 2 mM N-acetyl cysteine and
2 mM EDTA) for 16 h at 65°C. GAG was measured by reac-
tion with 1,9-dimethylmethylene blue using shark chon-
droitin sulphate as standard. DNA quantitation was carried
out using the PicoGreen® dsDNA Quantitation Kit (Invitro-
gen) with phage lambda DNA as standard as described pre-
viously [35]. Data was expressed as a ratio of GAG/DNA.
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Analysis of FoxP3 and TGF-b1 mRNA by reverse
transcription–polymerase chain reaction (RT–PCR)
and real-time PCR
Characterization of FoxP3 and TGF-b1 mRNA expression by
CD4+ T cells was performed using semi-quantitative and
quantitative (qRT–PCR). Purified CD4+ T cells (3 ¥ 105/ml)
and MSC (1 ¥ 105/ml) were co-cultured in 24-well plates
(Nunc, Roskilde, Denmark). In additional studies, anti-
TGF-b (R&D Systems) or indomethacin (Sigma-Aldrich,
Dublin, Ireland) were added to cultures at concentrations of
4 mg/ml and 40 mM respectively. After 24 h, non-adherent
CD4+ T cells were removed by aspiration leaving the adher-
ent MSC monolayer untouched using a simple method
described previously [15]. Purification of total RNA from
CD4+ T cell cultures was performed using the RNeasy® Plus
Mini kit (Qiagen, Crawley, UK) according to manufacturer’s
instructions, reverse-transcribed to cDNA and analysed for
the expression of human FoxP3 and TGF-b1 by a hot-
start RT–PCR reaction (Promega, Southampton, UK).
Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was
detected as an internal control. Primer sequences were as
follows: GAPDH forward 5′-GGTGAAGGTCGGAGTCA
ACG-3′ and reverse 5′-CAAAGTTGTCATGGATGACC-3′,
with an annealing temperature of 55°C; TGF-b1, annealing
at 54°C: forward 5′-CAGATCCTGTCCAAGCTG-3′; reverse
5′- TCGGAGCTCTGATGTGTT-3′; and FoxP3 annealing at
57°C: forward 5′-AGGTGGCAGGATGGTTTCT-3′; reverse
5′-AACAGCACATTCCCAGAGTTC-3′. Quantitative real-
time PCR analysis was performed using a QuantiTect™
SYBR Green PCR Kit (Qiagen) with a DNA Opticon™ quan-
titative thermocycler (MJ Research, Waltham, MA, USA)
[20].
Standard curves for each target gene were generated by
amplifying 10-fold serial dilutions of known quantities of
target gene PCR product standards. Quantification of target
gene expression was obtained using sequence detector
system software (MJ Research, Inc.). In this study the result-
ant target mRNA concentrations were expressed as fg/500 ng
cDNA.
Analysis of CD25 and FoxP3 protein expression by
flow cytometry
CD4+ T cells or PBMC were co-cultured with MSC in 2 ml
volumes in six-well plates (Nunc) or in transwells for 72 h as
described above. CD4+ T cells or PBMC were incubated at
0·5 ¥ 106 cells/ml and MSC at 1·5 ¥ 105/ml. Cells were
labelled for surface CD4 and CD25 and intracellular FoxP3.
Briefly, cells were incubated with CD4-PE or CD4-PE/Cy5
and CD25-PE or CD25-FITC or isotype-matched control
antibodies (eBioscience) for 15 min at 4°C then washed and
fixed by 2% (v/v) paraformaldehyde/PBS. Cells were per-
meabilized using cold PBS and 0·2% (v/v) Tween20/PBS
then blocked with normal rat serum. After blocking, cells
were incubated with fluorochrome-conjugated anti-human
FoxP3 (eBioscience) or isotype control for at least 30 min at
4°C in the dark. At the end of the incubation period, cells
were washed and resuspended in PBS containing 1% v/v
formaldehyde. Analysis was performed within 4 h of
preparation using BD fluorescence activated cell sorter
(FACS)Calibur and CellQuest software (BD Biosciences).
CD4+CD25+ functional assay
After 72 h co-culture of purified CD4+ cells and MSC, CD4+ T
cells were removed by aspiration and CD4+CD25+ cells
isolated using CD25 microbeads according to the manu-
facturer’s instructions (Miltenyi Biotech, Bisley, Surrey, UK).
CD4+CD25+ T cells were evaluated for their ability to suppress
allodriven proliferation in mixed lymphocyte reaction (MLR)
by co-culturing PBMC from two MHC mismatched donors
in 96-well plates, as described previously [20]. Proliferation
was measured using [3H]-thymidine incorporation for the
final 6 h of culture represented as the incorporated radioac-
tivity in counts per minute (cpm). Results are expressed as the
mean of triplicate values standard error (s.e.).
Statistical methods
Statistical significance was assessed using Prism3 software
(GraphPad Software, San Diego, CA, USA). Paired data were
analysed by paired t-test and three or more data sets were
compared using one-way anova, with Tukey’s multiple
comparison with measure significance. Data are presented as
the mean  s.e. P-values of P < 0·05 (*), P < 0·01 (**) or
P < 0·001 (***) were considered statistically significant.
Results
Characterization of human bone marrow-derived MSC
Human MSC derived from bone marrow displayed a fibro-
blastoid morphology and expressed surface markers typical
of adult MSC [36,37], including HLA-ABC, CD44, CD90
and CD106 (Fig. 1a). Human MSC did not express HLA-DR,
the haematopoietic cell markers CD34, CD117 or the
co-stimulatory molecules CD40, CD80 or CD86 (Fig. 1a).
Human MSC did not express CD29, CD54, CD105 or CD154
(Fig. 1a). Human MSC had the ability to differentiate along
the chondrogenic, osteoblastic or adipocytic pathways after
culture in the appropriate conditions (Fig. 1b and c).
Allogeneic MSC induce human CD4+CD25HighFoxP3+
T cells
Previous studies have suggested that MSC induce T cells with
a regulatory phenotype when co-cultured with PBMC.
However, these data are difficult to interpret, as multiple cell
types (CD8+ T cells, etc.) are present in such systems. There-
fore, this study sought to investigate whether allogeneic MSC
MSC induce CD4+CD25HighFoxP3+ Treg cells
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induced T cells with suppressive/regulatory activity using
defined purified populations of human CD4+ T cells. MSC
were co-cultured with MHC mismatched CD4+ T cells and
qRT–PCR used to quantify expression of the Treg transcrip-
tion factor, FoxP3. CD4+ T cells were cultured in the presence
or absence of MSC for 24 h. FoxP3 expression could be
observed in CD4+ T cells, cultured in the presence or absence
of MSC (Fig. 2a); however, there was a significant increase
(**P < 0·01) of FoxP3 in purified CD4+ T cells cultured pre-
viously in the presence of allogeneic MSC compared with
CD4+ T cells cultured alone (Fig. 2b).
mRNA concentration does not always correlate with
protein levels; therefore, FoxP3 and CD25 protein expression
were determined by flow cytometry. Purified CD4+ T cells
were cultured in the presence or absence of MSC for 72 h. In
the absence of MSC, small numbers of CD4+ T cells expressed
FoxP3 (Fig. 2c) or CD25 (Fig. 2c). In contrast, there was a
consistent increase in FoxP3 and CD25High expression after
co-culture with MSC (Fig. 2c). Thus MSC induce human
CD4+CD25HighFoxP3+ expression in allogeneic T cells.
Allogeneic MSC induction of FoxP3 and CD25High
expression by human T cells involves a cell
contact-dependent mechanism
In other systems, MSC-mediated immunomodulation
involves both cell contact-dependent and -independent
mechanisms mediated through the release of soluble factors.
In order to probe the role of cell contact, transwell experi-
ments were performed that prevented direct contact between
purified CD4+ T cells and allogeneic MSC. FoxP3 mRNA
expression was examined after 24 h using qRT–PCR. Sepa-
ration of MSC from CD4+ T cells prevented the induction of
FoxP3 mRNA (Fig. 3a). To investigate the correlation at the
protein level, CD4+ cells were recovered from the lower
chamber after 72 h of culture, and both FoxP3 and CD25
expression were analysed. When cell–cell contact was pre-
vented, allogeneic MSC did not induce FoxP3+ CD25+
expression in purified CD4+ cells (Fig. 3b). Consistently
fewer CD4+ T cells expressed FoxP3 and CD25High when
compared with cultures where cell contact was permitted
(Fig. 3a and b). In separate experiments, the importance of
other immune cells in MSC induction of FoxP3 expression
was examined. Unseparated PBMC were cultured in the
presence or absence of MSC in regular cultures or in a tran-
swell system that prevented cell contact. PBMC were recov-
ered after 72 h and FoxP3 and CD25 expression analysed by
flow cytometry. Although co-culture of PBMC with MSC
resulted in increased expression of FoxP3 and CD25, preven-
tion of cell contact did not interfere with MSC induction of
FoxP3 and CD25, indicating that in the presence of other
immune cells, cell contact is not required (Fig. 3c). Taken
together, these data show that cell–cell contact contributes to
MSC-driven Treg induction in purified CD4+ T cells, but that
in a multi-cell system such as PBMC additional factors can
substitute for cell contact-derived signals.
The TGF-b1 and PGE2 play a non-redundant role in
MSC induction of human CD4+ CD25High FoxP3+ T cells
The observed role for cell contact in Treg induction in CD4+ T
cells does not exclude the possibility that soluble factors play
a non-redundant role in Treg induction, and indeed the data
in Fig. 3c support an important role for soluble factors in
MSC induction of Treg. In other systems, PGE2 contributes to
the induction of FoxP3 [33], and we have demonstrated
previously that PGE2 secreted by human MSC was required
for modulation of allodriven proliferation in MLR [20].
TGF-b1 is also known to be involved in Treg induction [38],
and moreover is up-regulated in MSC ‘licensed’ by IFN-g
stimulation [20]. Therefore, the effects of blocking both
factors in allogeneic MSC : purified CD4+ T cell co-cultures
were examined. Cyclooxygenase activity and therefore PGE2
induction was ablated using the antagonist indomethacin,
whereas TGF-b1 was neutralized by a well-characterized
antibody. The presence of indomethacin or anti-TGF-b1
alone resulted in a significant decrease in FoxP3 mRNA
expression by CD4+ T cells cultured with allogeneic MSC
(Fig. 4a). However, a combination of both reduced FoxP3
mRNA to background levels (Fig. 4a). Neutralization of
TGF-b resulted in decreased protein expression of both
intracellular FoxP3 and surface CD25High by purified CD4+
cells following co-culture (Fig. 4b and c) and antagonism of
PGE2 production produced a similar effect (Fig. 4b and c).
This indicates that although cell contact is involved in MSC
induction of human CD4+ CD25High FoxP3+ T cells, both
TGF-b1 and PGE2 play non-redundant roles in this process.
In effect, both cell contact and soluble factors are required
for MSC induction of CD4+ Treg cells. The transwell experi-
ments show that cell contact is required and soluble factors
are not sufficient to achieve this. The neutralization study
which allowed cell contact demonstrated that TGF-b1 and
Fig. 1. Characterization and differentiation potential of human mesenchymal stromal cells (MSC). (a) Cell surface markers expressed by human
MSC were determined by flow cytometry. Isotype controls are represented by open histograms, specific cell surface markers by closed histograms.
The capacity of MSC to differentiate along mesenchymal lineages was also determined by: (b) phase-contrast microscopy (magnification ¥ 200)
of (i) control, undifferentiated MSC; (ii) adipogenic differentiated MSC, determined by oil red O staining; (iii) osteogenic differentiated MSC
determined by alizarin red S staining; or (c) glycosaminoglycan content, an indicator of chondrogenic differentiation, determined using a
1,9-dimethylmethylene blue assay and a picogreen DNA assay for undifferentiated and differentiated MSC (n = 2). Differentiation conditions are
described in Methods. Data are represented as the mean  standard error ratio of GAG/DNA (mg/mg). *P < 0·05 compared with undifferentiated
MSC.

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PGE2 are the effector molecules involved in the induction of
Treg in the absence of other immune cells.
Human CD4+CD25+ T cells induced by allogeneic MSC
act as conventional Treg
Blockade of cytokine production from CD4+ T cell/MSC
co-cultures is a straightforward technique to determine a role
for cytokines in Treg induction; however, this method does not
provide information of the functional activity of the induced
T cell. Therefore CD4+ T cells, cultured in previously the
presence or absence of MSC for 24 h, were re-isolated from
the adherent monolayer of MSC. TGF-b1 mRNA was signifi-
cantly higher in CD4+ T cells that had been co-cultured with
MSC (Fig. 5a and b), supporting hypotheses that MSC-
derived signals condition the local tissue environment to
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Fig. 2. Exposure to mesenchymal stromal cells (MSC) increases CD4+ T cell expression of CD25 and forkhead box P3 (FoxP3). CD4+ T cells were
cultured in the absence (CD4) or presence of MSC (CD4+MSC), purified and examined by either (a) semi-quantitative reverse transcription–
polymerase chain reaction (RT–PCR) for the expression of glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) or FoxP3 mRNA after 24 h
co-culture; or (b) quantitative real-time PCR for FoxP3 mRNA. **P < 0·01 compared with CD4+ T cells alone. Data representative of three
independent determinations. Intracellular expression of FoxP3 or surface CD25 from parallel experiments were determined by flow cytometry from
purified CD4+ cell populations (c). CD4+FoxP3+ or CD4+CD25High cells were determined from purified CD4+ T cells following 72 h culture in the
absence (top panel) or presence of MSC (lower panel). Dot plots are representative of three independent experiments. The numbers in the upper
right quadrants indicate the percentage of double-positive cells (large font) with mean fluorescent intensity (MFI) above (small font).
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Fig. 3. Prevention of T cell–mesenchymal
stromal cells (MSC) contact reduced forkhead
box P3 (FoxP3) and CD25High induction in
CD4+ T cells. CD4+ T cells or unseparated
peripheral blood mononuclear cells (PBMC)
were cultured with MSC for 72 h or separated
in co-culture using a transwell system with
MSC in the upper chamber and CD4+ T cells or
unseparated PBMC in the lower. FoxP3 mRNA
concentration in CD4+ cells was determined by
quantitive reverse transcription–polymerase
chain reaction (qRT–PCR) (a). Intracellular
FoxP3 or surface CD25 protein expression by
CD4+ T cells (b) or unseparated PBMC (c) was
determined by flow cytometry. CD4+ T cells
(CD4) and unseparated PBMC cultured alone
are shown for comparison. Data are
representative of three experiments. The
numbers in the upper right quadrants indicate
the percentage of double-positive cells
(large font) with MFI above (small font).
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promote induction of T cells secreting this immunosuppres-
sive cytokine [16,39]. Nevertheless, the induction of CD4+
cells secreting TGF-b1 is insufficient to describe these cells as
Tregs. Similarly, the induced expression of CD25 does not
necessarily define these as Tregs, because CD25 is also
expressed by recently activated T cells. To ascertain whether
MSC generate functional Tregs, CD4+CD25+ T cells induced by
allogeneic MSC were purified and examined for their sup-
pressive activity in MLR. After 72 h MSC co-culture,
CD4+CD25+ cells were retrieved using CD25+ microbeads and
were added subsequently to MLR containing PBMC from
mismatched donors. CD4+CD25+ cells induced by allogeneic
MSC secreted TGF-b1 (Fig. 5a and b) and reduced allodriven
proliferation significantly (Fig. 5c). Thus CD4+CD25+ T cells
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Fig. 4. Transforming growth factor (TGF)-b1 and prostaglandin E2 (PGE2) play a non-redundant role in mesenchymal stromal cells (MSC)
induction of forkhead box P3 (FoxP3) and CD25High expression by CD4+ T cells. (a) FoxP3 mRNA expression determined by real-time polymerase
chain reaction (PCR) of CD4+ T cells purified from culture alone (CD4) or in the presence of MSC and/or the cyclooxygenase-2 antagonist (Indo)
(40 mM) and/or neutralizing specific antibody against TGF-b1 (aTGF-b1) (4 mg/ml). MSC induced significant FoxP3 expression in CD4+ T cells.
Addition of anti-TGF-b1 or indomethacin (40 mM) to CD4+ T cells co-cultured with MSC significantly reduced FoxP3 mRNA expression).
Statistical analysis was performed by one-way anova with Tukey’s multiple comparisons; results are expressed as mean concentration  standard
error. *P < 0·05; **P < 0·01). Analysis of intracellular FoxP3 (b) and CD25High surface expression (c), by purified CD4+ T cell from parallel
co-cultures. Data are representative of three experiments. The numbers in the upper right quadrants indicate the percentage of double-positive cells
(large font) with MFI given above (small font).
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induced by allogenic MSC displayed conventional suppres-
sive activity consistent with definitions of Tregs.
Discussion
An understanding of the mechanisms by which MSC modu-
late allogeneic reactivity will be critical to the approval
process for new therapies involving regenerative medicine.
The current study examined the mechanisms of MSC induc-
tion of human Tregs relevant to peripheral tolerance. Alloge-
neic MSC co-cultured with purified CD4+ T cells resulted in
a significant increase in FoxP3 expression. Direct MSC–T cell
contact was required for FoxP3 and CD25High expression by
CD4+ T cells; however, soluble MSC-derived factors also
played a non-redundant role. In particular, both TGF-b1 and
PGE2 derived from MSC contributed to allogeneic MSC
induction of FoxP3+CD25+CD4+ T cells. CD4+CD25+ T cells
induced by encounter with MSC suppressed alloantigen-
driven proliferation. Therefore, MSC induce CD4+ T cell
populations with all the characteristics of Treg through a
process involving MSC derived PGE2 and TGF-b1, subse-
quent to the prerequisite of cell contact.
The MSC have attracted attention by virtue of their dif-
ferentiation capacity and therapeutic potential, offering a
new frontier in regenerative medicine [16]. The immuno-
suppressive properties of MSC have great significance with
respect to the potential clinical application of MSC. A variety
of studies have shown beneficial effects of MSC therapy in a
number of disease models, including osteoarthritis [6], dia-
betes [40] and myocardial infarction [41], and successful
outcomes from transplantation studies using MSC for treat-
ing GVHD [42,43], autoimmune disorders [44,45], metach-
romatic leucodystrophy and Hurler syndrome [46] and
stroke [47], as well as repair of damaged tissue [48,49]. Many
of these studies encourage the potential use of allogeneic
MSC in regenerative medicine.
The realization that direct MSC–T cell interaction induces
T cells with regulatory properties has emerged from a
number of reports examining the broader question of MSC
immunomodulation. Initial studies by Beyth et al. [50] and
Maccario et al. [28] noted the induction of cells with phe-
notypic characteristics of Treg but did not involve functional
studies of suppression. Li et al. have shown similar findings
using placental-derived multi-potent stem cells [51]; this
observation is interesting, as it again highlights the similari-
ties between immunomodulation at the feto–maternal
interface [39] and those operating during repair [52–54].
Aggarwal et al. extended these observations by showing that
MSC induce a glucocorticoid-induced T cell receptor
(GITR)+ T cell and demonstrated suppressor activity in
a PBMC co-culture system; however, the mechanism
remained unclear [21]. The present study supports those
findings and clarifies an important non-redundant contri-
bution to PGE2 and TGF-b1 in the MSC induction of
FoxP3+CD4+CD25+ T cells with direct suppressor activity.
These findings are in contrast with studies of Provosto
et al.; although that group showed CD25+ and GITR+/
cytotoxic T lymphocyte associated antigen-4+ T cell induc-
tion with suppressor activity, no role for PGE2, TGF-b or
IL-10 was observed [55]. These contradictory data relating to
TGF-b and PGE2 are difficult to resolve, but may be due to
differences in MSC isolation. The human MSC used in this
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Fig. 5. Purified CD4+ CD25+ T cells induced by mesenchymal stromal cells (MSC), expressed transforming growth factor (TGF)-b1 and suppressed
alloresponses. TGF-b1 mRNA was increased in purified CD4+ T cells cultured previously in the presence of MSC determined by reverse
transcription–polymerase chain reaction (RT–PCR) (a) and quantified by real-time PCR for TGF-b1 mRNA (b). Real-time PCR showed a
significant (***P < 0·001) increase in TGF-b1 expression by CD4+ T cells co-cultured previously with MSC for 24 h compared with CD4+ T cells
alone. Results are representative of three independent experiments each performed in duplicate, expressed as mean concentration standard error
(s.e.). Purified CD4+CD25+ T cells induced by MSC co-culture suppressed alloantigen-driven proliferation in mixed lymphocyte reaction (MLR) (c).
Microbead purified CD4+CD25+ T cells induced from co-cultured with MSC were then cultured with or without MHC mismatched donor cells
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study are well characterized [20], and do not express HLA-
DR. Alternatively, as the readout for suppression used by
Prevosto et al. involved a multi-cell system, whereas the
present work examined only the suppressive effect of a puri-
fied CD4+CD25+ population, it might well be that in a more
complex readout system the specific role of individual
mediators could be masked by other mechanisms [55]. This
is indeed likely, as we have shown previously in murine
systems that multiple independent pathways modulate dif-
ferent aspects of suppression [15,19].
Very recently, Selmani et al. have demonstrated a role for
HLA-G5 in MSC mediated suppression using an MSC–
PBMC system, and demonstrating an important role for
cell–cell contact in Treg functional suppression [56]. The data
herein are consistent with that study. Using a different
approach involving purified cells, we show that direct cell
contact is required between the MSC and the CD4+ T cell to
achieve maximum induction of FoxP3, CD25+ CD4+ T cells.
Thus a model is emerging where MSC directly modulate T
cell polarization involving a cell contact step, and MSC pro-
duction of HLA-G, followed by PGE2 and TGF-b1 signalling
to the CD4+ T cell. In summary, both contact-dependent and
-independent interactions are required, most probably in a
sequential manner, and this phenomenon is analogous
to T cell help for B cells requiring both cell contact and
soluble factors [57]. In this study we also examined the
importance of other immune cells in MSC induction of
CD4+CD25+FoxP3+ Treg cells using unseparated PBMC. This
complex system of MSC co-culture with PBMC might reflect
a situation in a complex immunological milieu and be
informative. The only difference to the above system is that
while cell contact is required for the MSC-driven induction
of FoxP3 in CD4+ T cells, in the unseparated PBMC system
there is no such requirement for cell contact for MSC induc-
tion of FoxP3 expression (Fig. 3c). Presumably in such an
environment contact signals are substituted by other soluble
factors not present in the two-cell system.
This study has focused upon the direct induction of Treg by
MSC; however, MSC can also induce Tregs via an indirect
route, through modulation of DC maturation. Previously,
using murine and human systems we and others have dem-
onstrated that MSC veto DC maturation marker expression,
chemokine receptor switch, antigen display and antigen
presentation function, while preserving DC expression of
tissue-anchoring E-cadherin [12,15,58–60]. This can lead to
Treg induction via an indirect route that requires IL-6 [15].
Furthermore, specific aspects of immune function can be
modulated by kynurenine concentration [20], IDO [61],
haem oxygenase, insulin-like growth factor binding protein
and other MSC-derived factors [22–24]. The major point is
that MSC modulate immunity by multiple inter-related
pathways, but that clarification of the mechanisms involved
relies on highly defined populations and systems.
The aim of this study was to determine if MSC mediate
their suppressive effect by inducing CD4+ T cells to a regu-
latory phenotype. This study showed clearly that allogeneic
human MSC have the ability to modulate CD4+ T cell func-
tion directly. Herein it is shown that the immunosuppressive
function of MSC is conducive to the development of a sup-
pressor or Treg phenotype, with a corresponding increase in
TGF-b1 expression, which is known to suppress the devel-
opment of an effector T cell response. These findings suggest
that MSC induce CD4+CD25HighFoxP3+ T cells to modulate
alloresponses from an effector to a suppressive or regulatory
response and thereby interfere with the immune response to
alloantigen. This hypothesis is amenable to testing and is
supported by human clinical studies of MSC in the preven-
tion of allograft rejection, GVHD, chronic inflammatory
disease and autoimmunity [62–64]. Recent reports have sug-
gested a broad role for TGF-b1 and PGE2 in the genera-
tion and expansion of Treg from CD4+CD25- precursors
[33,38,65–67]. A report by Fu et al. demonstrated that
TGF-b signalling is a key regulator of the signalling pathway
that initiates and maintains FoxP3 expression and suppres-
sor function [38]. Interestingly, human MSC express con-
stitutively both TGF-b1 and PGE2 [20], but both are signifi-
cantly up-regulated upon ‘licensing’ by inflammatory media-
tors [19,20]. Therefore, this study proceeded to determine if
MSC-derived soluble factors were responsible for Treg induc-
tion by blocking PGE2 and TGF-b1 with indomethacin and
anti-TGF-b respectively. Several studies have demonstrated
the ability of CD4+CD25+ regulatory cells to suppress allore-
activity and can attenuate GVHD [68,69]. Consistent with
this role for Tregs, CD4+CD25+ T cells that were retrieved from
MSC/CD4+ T cell co-cultures displayed allosuppressive func-
tion when added to an MLR containing allogeneic PBMC.
Djouad and colleagues have demonstrated that MSC
induction of CD8+ Treg was responsible for certain immuno-
suppressive activities of MSC in vitro [70]. In contrast to these
data, Krampera et al. showed that CD4+CD25+ regulatory
cells were not required for the inhibitory activity mediated by
MSC [10]. However, this does not contradict the present
study; we have demonstrated previously that immunomodu-
lation occurs by multiple redundant pathways of which CD4+
Treg induction is only one [15,19,20]. Furthermore, we have
shown previously that some discrepancies may be explained
by differences between murine and human MSC, in particular
in our hands unlicensed human MSC,unlike murine MSC,do
not express IL-10 constitutively [19,20].
The discovery of MSC modulation of allogeneic responses
was greeted with some scepticism by immunologists;
however, it is now clear that MSC modulate immunity by
multiple different factors. This process involves cross-talk or
licensing from immune and inflammatory signals, and may
be a fundamental aspect of peripheral tolerance induction to
neo-antigens during adult tissue repair [71]. The present
study demonstrates a novel non-redundant role for cell
contact and both TGF-b1 and PGE2 in MSC induction of
regulatory CD4+ T cells expressing FoxP3. This definition of
the precise mechanisms involved in allosuppression support
K. English et al.
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the proposed use of allogeneic MSC in human clinical trials
and provides a rational scientific basis for the observations
seen in the use of allogeneic MSC as a novel therapy against
GVHD.
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